Emv Capital Plc · LSE:EMVC
Emv Capital — NetScientific — Mello2023 Investor Conference (May 2023)
14 slides from Emv Capital's conference presentation, May 23, 2023
Slide 1: Differentiated PLC Investment Model Designed for Deeptech
Differentiated PLC Investment Model Designed for Deeptech Dr. Ilian Iliev, CEO Mello2023 Investor Conference 23 May 2023
Slide 2: Disclaimer
Disclaimer This presentation (and any information contained in any oral presentation accompanying it) (Presentation) has been prepared by NetScientific Plc (Company). This Presentation has not been approved by an authorised person in accordance with Section 21 of the Financial Services and Markets A
Slide 3: About NetScientific
About NetScientific NetScientific plc (AIM: NSCI) is an investment and commercialisation group with focus on life sciences, sustainability, industrials • NS acquisition of Deeptech specialist EMV Capital in September 2020 transformed the company from a standstill into a scalable VC business • Identi
Slide 4: Effective Board Leadership & Corporate Governance
Effective Board Leadership & Corporate Governance Dr. Ilian Iliev, CEO Ed Hooper, Executive Director and Group General Counsel • Founder of EMV Capital – acquired by NetScientific PLC in 2020 • Former Partner of a City headquartered international law firm • Significant shareholder of NetScientific (
Slide 5: Growth Strategy Key Levers
Growth Strategy Key Levers • Proactive management: Board representation in 13 companies • “Capital light” investment: leveraging NS balance sheet & Plc status for syndicated funding • Value Creation: value creation or fundraising programs with 10 companies • Cohort focus approach: deeper direct stak
Slide 6: Group Portfolio – Diversified Risk and Increased Investment Return Opportunities
Group Portfolio – Diversified Risk and Increased Investment Return Opportunities 24 companies in Life Sciences, Deeptech and Sustainability segments NASDAQ-listed *Portfolio comprises of equity investments and exposure to companies through carried interest, realisable on exit BALANCED PORTFOLIO FOR
Slide 7: Advantages of Model
Advantages of Model • Capital light investment strategy: enables NetScientific to support its portfolio companies with a very selective use of its balance sheet • Proactive investment approach: opens up value opportunities, investments on advantageous conditions • Value creation services: selective
Slide 8: 2022 Trading Update: Progress Despite Challenging Market Conditions
2022 Trading Update: Progress Despite Challenging Market Conditions • Continued fair value growth (from £31m at end of 2021): Reflecting pro-active management, key value creation projects and fund-raisings • Portfolio: Selectively participated in/led 10 investments through both direct and syndicated
Slide 9: Active Portfolio Management and Value Creation
Active Portfolio Management and Value Creation Concentrating on a “cohort” of companies, taking deeper stakes, with a focus on value creation and investment realisations Selective new investments that align with our model, offer good value, and can benefit from value creation services CONTINUED SUPP
Slide 10: Portfolio Highlights: Selective Deeper Involvement
Portfolio Highlights: Selective Deeper Involvement Vortex, US-UK (liquid biopsy, oncology, Q-Bot, UK (robotics as a service, home retrofit PDS Biotechnology Corp, NASDAQ:PDSB 30% direct) insulation, 17.6% direct, 30.9% under advisory) (Immuno-oncology, c.4.7% share) • Mature robotics technology comp
Slide 11: Portfolio Highlights: Selective Deeper Involvement
Portfolio Highlights: Selective Deeper Involvement Martlet Capital Ltd (Cambridge) Deeptech Recycling Ltd (30% direct stake) • Originated and drove strategy to acquire the assets of Recycling • A leading early-stage VC in Cambridge Technologies Ltd from the Administrator • 49 portfolio companies in
Slide 12: Outlook: NSCI Strategic Objectives FY2023+
Outlook: NSCI Strategic Objectives FY2023+ Progress Sustainable Business Model • The generation of more fees from EMV Capital • Selective divestments • External funding for subsidiaries • Expand funds practice Increase the NAV and Fair Value • Progress portfolio companies through value creation stag
Slide 13: Summary - Q&A
Summary - Q&A Transformed business, a robust investment model • Maturing portfolio with added potential, drive for exits/liquidity events • Management commitment and focus, well placed and flexible • Align underlying (and increasing) asset value with market cap • Strong fees and deals pipeline for 2
Slide 14: Impact and Recognition
Impact and Recognition 6 netscientific Merck KGaA hands over IL-12- targeting cancer med to PDS Biotech in $121M deal y ad r I < PDS Biotech Announces 100% Clinical Response in Cervical Cancer Patients in Preliminary Data from IMMUNOCERV Phase 2 Clinical Trial Sofant Technologies signs €7.3 million
NetScientific — Mello2023 Investor Conference (May 2023) on 6ix